BIO
Bio-Rad Laboratories, Inc.
Healthcare · Medical Devices · NYQ
$294.32
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$8.2B
Total market value of the company
50.80
Expensive — high growth expected
31.40
Based on estimated future earnings — lower means cheaper
Rev Growth
+1.1%
Year-over-year revenue change
Profit Margin
6.5%
How much profit the company keeps from each dollar of revenue
2.5%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$300.00
+2% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 5 analysts covering this stock
About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

https://www.bio-rad.com

Country: United States Employees: 7,450 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
0.338
Positive but modest risk-adjusted returns
0.0300
Modest edge detected — smaller position warranted
0.135
Drawdown risk outweighs the returns — higher risk profile
Annual Return
5.7%
Historical annualised return based on price data
-42.1%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
5
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

1.06
Moves slightly more than the broader market
52W High
$343.12
14% below the year high
52W Low
$211.43
39% above the year low
Avg Volume
357,244
Average daily shares traded — higher means easier to buy and sell
0.0
Days it would take all short sellers to cover — higher means more crowded
Short % Float
N/A
N/A
Annual dividend as a percentage of the share price
$6.00
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

20.12
Heavy leverage — higher financial risk if revenues decline
3.21
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
2.19
Like current ratio but excludes inventory — stricter test
Gross Margin
52.0%
Revenue left after cost of goods — higher means pricing power
Operating Margin
5.8%
Profit from core operations before interest and tax
$230M
Positive — the business generates more cash than it spends
Revenue (TTM)
$2.6B
Total revenue over the last 12 months
Net Income
$169M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
5
Target High
$320.00
Target Median
$300.00
Target Low
$275.00
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Sale 1K–15K
2026-04-13 Ro Khanna Democrat Sale 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.